| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/06/2005 | WO2005039553A1 Compositions for the treatment and prevention of cancer |
| 05/06/2005 | WO2005039552A2 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives |
| 05/06/2005 | WO2005039551A2 Solid pharmaceutical dosage form comprising an hiv protease inhibitor solid dispersion |
| 05/06/2005 | WO2005039550A2 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds |
| 05/06/2005 | WO2005039549A1 Indolyl-pyrroledione derivatives for the treatment of neurological and vascular disorders related to beta-amyloid generation and/or aggregation |
| 05/06/2005 | WO2005039548A2 Use of effectors of glutaminyl and glutamate cyclases |
| 05/06/2005 | WO2005039547A1 Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents |
| 05/06/2005 | WO2005039546A2 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 05/06/2005 | WO2005039545A1 Oral antidepressant formulation comprising acetylsalicylic acid to accelerate onset of action |
| 05/06/2005 | WO2005039541A1 Coenzyme q10 enclosing capsule |
| 05/06/2005 | WO2005039540A1 Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative |
| 05/06/2005 | WO2005039539A1 ORAL FORMULATION OF LIPID SOLUBLE THIAMINE, LIPOIC ACID, CREATINE DERIVATIVE, AND L-ARGININE α-KETOGLUTARATE |
| 05/06/2005 | WO2005039538A1 Process for producing coated preparation having relieved unpleasantness |
| 05/06/2005 | WO2005039537A1 Composition comprising biodegradable hydrating ceramics for controlled drug delivery |
| 05/06/2005 | WO2005039535A1 Preparation of lipid particles |
| 05/06/2005 | WO2005039533A1 Method of administering cationic liposomes comprising an active drug |
| 05/06/2005 | WO2005039532A1 Microemulsions of retinoids, and pharmaceutical compositions containing them |
| 05/06/2005 | WO2005039530A1 Methods and compositions for treating erectile dysfunction |
| 05/06/2005 | WO2005039529A1 Microsphere of two anti-tubercular drugs and a biodegradable polymer administered by inhalation alone or combined with oral route, and process thereof |
| 05/06/2005 | WO2005039527A2 Extended release pharmaceutical dosage form |
| 05/06/2005 | WO2005039523A1 Composition comprising a sesquiterpene lactone |
| 05/06/2005 | WO2005039518A1 Oral compositions comprising erythritol for the treatment of dental-plaque and oral infections |
| 05/06/2005 | WO2005039507A2 Antimicrobial and antiviral compounds |
| 05/06/2005 | WO2005039504A2 Compounds and methods for treating toll-like receptor 2-related diseases and conditions |
| 05/06/2005 | WO2005039503A2 Prenylation inhibitors reduce host cell permissiveness to viral replication |
| 05/06/2005 | WO2005039502A2 Macromer-melt formulations |
| 05/06/2005 | WO2005039500A2 METHOD FOR THE PRODUCTION OF BIOACTIVE SUBSTANCES FROM THE NOVEL ACTINOMYCETE TAXON MAR2 (“Marinophilus”) |
| 05/06/2005 | WO2005039499A2 Rapidly disintegrating film |
| 05/06/2005 | WO2005039498A2 Methods of treating cancer with hdac inhibitors |
| 05/06/2005 | WO2005039497A2 Methods and compositions comprising thalidomide for treatment of fibromyalgia |
| 05/06/2005 | WO2005039496A2 Inhibitors of cathepsin s |
| 05/06/2005 | WO2005039494A2 Inhibitors of rnase p proteins as antibacterial compounds |
| 05/06/2005 | WO2005039489A2 Compositions and methods for the inhibition of bone growth and resorption |
| 05/06/2005 | WO2005039486A2 Compounds and compositions as protein kinase inhibitors |
| 05/06/2005 | WO2005039485A2 Gsk-3 inhibitors and uses thereof |
| 05/06/2005 | WO2005039484A2 Indolocarbazole anticancer agents and methods of using same |
| 05/06/2005 | WO2005039483A2 Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| 05/06/2005 | WO2005039482A2 Utilization of vinpocetine to avoid complications in particular those associated to hearing which occur with epilepsy, and treatment thereof |
| 05/06/2005 | WO2005039443A2 Gamma-tocopherol therapy for restenosis prevention |
| 05/06/2005 | WO2005039320A2 Composition for the activation of the immune system |
| 05/06/2005 | WO2005039319A2 Synbiotic composition for infants |
| 05/06/2005 | WO2005030753A3 Therapeutic agents useful for treating pain |
| 05/06/2005 | WO2005027895A3 Thyroid hormone analogs and methods of use in angiogenesis |
| 05/06/2005 | WO2005025586B1 Cytokine modulators and related method of use |
| 05/06/2005 | WO2005025499A3 Hydrophobic drug compositions containing reconstitution enhancer |
| 05/06/2005 | WO2005021541A3 Process for the production of polymorphs of rosiglitazone maleate |
| 05/06/2005 | WO2005020926A3 Treatment or prevention of vascular disorders with cox-2 inhibitors in combination with cyclic amp-specific phosphodiesterase inhibitors |
| 05/06/2005 | WO2005020904A3 Oral neurotherapeutic cefazolin compositions |
| 05/06/2005 | WO2005019240A3 Melanin concentrating hormone receptor antagonists |
| 05/06/2005 | WO2005018624A3 Methods of treating copd and pulmonary hypertension |
| 05/06/2005 | WO2005018573A3 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
| 05/06/2005 | WO2005017094A3 N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency |
| 05/06/2005 | WO2005013902A3 Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| 05/06/2005 | WO2005011656A3 Pyridyl derivatives and their use as therapeutic agents |
| 05/06/2005 | WO2005009949A3 17-acetamido-4-azasteroid derivatives as androgen receptor modulators |
| 05/06/2005 | WO2005009436A8 Dispersible formulation of an anti-inflammatory agent |
| 05/06/2005 | WO2005007828A3 Regulation of hif protein levels via deubiquitination pathways |
| 05/06/2005 | WO2005007239B1 Use of dapsone as a neuroprotector in cerebral infarction |
| 05/06/2005 | WO2005005395A3 Arylamine-substituted quinazolinone compounds |
| 05/06/2005 | WO2005004849A3 Pharmaceutical formulation comprising levothyroxine sodium |
| 05/06/2005 | WO2005000288A3 Treatment of protein aggregation disorders |
| 05/06/2005 | WO2004112710A3 COMPOSITIONS AND METHODS FOR INHIBITING TGF-ß |
| 05/06/2005 | WO2004104018A3 Compositions for delivering peptide yy and pyy agonists |
| 05/06/2005 | WO2004103959A3 Heterocyclic compounds and uses thereof |
| 05/06/2005 | WO2004103057A3 Compositions and methods for inducing adipose tissue cell death |
| 05/06/2005 | WO2004100994A3 Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances |
| 05/06/2005 | WO2004096287A3 Inosine monophosphate dehydrogenase inhibitory phosphonate compounds |
| 05/06/2005 | WO2004096218A3 Pellet formulations of acid-labile antiulcer benzimidazole compounds |
| 05/06/2005 | WO2004096194A3 Prevention of hiv-1 infection by inhibition of rho-mediated reorganization and/or content alteration of cell membrane raft domains |
| 05/06/2005 | WO2004092116A8 Bicyclic compounds having bradykinin receptors affinity and pharmaceutical compositions thereof |
| 05/06/2005 | WO2004091547A3 Compounds, compositions, and methods |
| 05/06/2005 | WO2004091539A3 Fluid mixing methods and apparatus |
| 05/06/2005 | WO2004091537A3 Process for making gel films |
| 05/06/2005 | WO2004089880A3 Carbamates useful as fragances |
| 05/06/2005 | WO2004089304A3 Antiandrogens with marginal agonist activity and methods of use |
| 05/06/2005 | WO2004087132A8 Combination drug therapy for treating hypertension |
| 05/06/2005 | WO2004082638A3 Histone deacetylase inhibitors |
| 05/06/2005 | WO2004080488A3 Combined preparations of acetyl salicylic acid with an hmg-coa reductase inhibitor |
| 05/06/2005 | WO2004080383B1 Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels |
| 05/06/2005 | WO2004078180A3 Naaladase inhibitors for treating opioid tolerance |
| 05/06/2005 | WO2004067505A3 Bismuth dithiocarbamate compounds and uses thereof |
| 05/06/2005 | WO2004064736A3 Treatment of benign prostatic hyperplasia using energolytic agents |
| 05/06/2005 | WO2004064725A3 Oral compositions and methods for treatment of adverse effects or radiation |
| 05/06/2005 | WO2004062614A3 Carbohydrate conjugates to prevent abuse of controlled substances |
| 05/06/2005 | WO2004047727A3 Compositions and methods for diagnosing and treating mood disorders |
| 05/06/2005 | WO2004032823A8 Treatment and rehydration composition which is used to limit the side effects of gastro-enteritis in adults |
| 05/06/2005 | WO2004019901A3 Sustained release pharmaceutical composition |
| 05/06/2005 | WO2004015096A8 Leech extracts for stents |
| 05/06/2005 | WO2004002939A3 Aminoalcohol derivatives |
| 05/06/2005 | WO2003072607A8 Monoclonal antibodies that are cross-reactive against bacterial collagen binding proteins |
| 05/06/2005 | WO2003068746A8 Aryl ureas as kinase inhibitors |
| 05/06/2005 | WO2003068146A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/06/2005 | WO2003062394A3 Methods and compositions for rna interference |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2782783A1 Fused heterocyclic compounds |
| 05/06/2005 | CA2689639A1 Solid pharmaceutical dosage form |
| 05/06/2005 | CA2585024A1 Macromer-melt formulations |
| 05/06/2005 | CA2546737A1 Method for the production of bioactive substances from the novel actinomycete taxon mar2 ("marinophilus") |
| 05/06/2005 | CA2546203A1 Extended release tablet formulations of venlafaxine |